Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Oral Immunotherapy for Food Allergy -The FAST perspective.

Wasserman RL, Jones DH, Windom HH.

Ann Allergy Asthma Immunol. 2018 Jun 18. pii: S1081-1206(18)30483-6. doi: 10.1016/j.anai.2018.06.011. [Epub ahead of print] No abstract available.

PMID:
29928983
2.

Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients.

Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, Herbert M.

J Allergy Clin Immunol Pract. 2018 May 30. pii: S2213-2198(18)30345-3. doi: 10.1016/j.jaip.2018.05.023. [Epub ahead of print]

PMID:
29859333
3.

Correction to: Use of Genetic Testing for Primary Immunodeficiency Patients.

Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Itan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Bleesing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.

J Clin Immunol. 2018 May;38(4):540-541. doi: 10.1007/s10875-018-0510-2.

PMID:
29781065
4.

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Ballow M, Wasserman RL, Jolles S, Chapel H, Berger M, Misbah SA.

J Clin Immunol. 2018 May;38(4):539. doi: 10.1007/s10875-018-0504-0.

5.

Use of Genetic Testing for Primary Immunodeficiency Patients.

Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Blessing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.

J Clin Immunol. 2018 Apr;38(3):320-329. doi: 10.1007/s10875-018-0489-8. Epub 2018 Apr 19. Erratum in: J Clin Immunol. 2018 May 21;:.

PMID:
29675737
6.

Balancing the risks and burdens of food allergen avoidance.

Wasserman RL.

Ann Allergy Asthma Immunol. 2018 Mar;120(3):229-230. doi: 10.1016/j.anai.2018.01.022. No abstract available.

PMID:
29391201
7.

RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations.

Wasserman RL, Greener BN, Mond J.

Expert Rev Clin Immunol. 2017 Dec;13(12):1107-1119. doi: 10.1080/1744666X.2017.1389647. Epub 2017 Oct 16. Review.

PMID:
29035131
8.

Gammaplex® 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura.

Wasserman RL.

Immunotherapy. 2017 Oct;9(13):1071-1088. doi: 10.2217/imt-2017-0071. Epub 2017 Sep 18. Review.

PMID:
29032734
9.

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.

Wasserman RL.

Immunotherapy. 2017 Sep;9(12):1035-1050. doi: 10.2217/imt-2017-0092. Epub 2017 Sep 5. Review.

10.

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Aug;37(6):613. doi: 10.1007/s10875-017-0418-2. No abstract available.

PMID:
28714047
11.

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Ballow M, Wasserman RL, Jolles S, Chapel H, Berger M, Misbah SA.

J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10. No abstract available. Erratum in: J Clin Immunol. 2018 Apr 27;:.

12.

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Apr;37(3):301-310. doi: 10.1007/s10875-017-0383-9. Epub 2017 Mar 18. Erratum in: J Clin Immunol. 2017 Jul 17;:.

13.

Case Studies.

Shapiro RS, Wasserman RL, Bonagura V, Gupta S.

J Clin Immunol. 2017 Feb;37(2):188-189. doi: 10.1007/s10875-013-9929-7. Epub 2013 Aug 20. No abstract available.

PMID:
28236086
14.

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.

Wasserman RL, Ito D, Xiong Y, Ye X, Bonnet P, Li-McLeod J.

J Clin Immunol. 2017 Feb;37(2):180-186. doi: 10.1007/s10875-017-0371-0. Epub 2017 Feb 3.

15.

Identification and Characterization of Ana o 3 Modifications on Arginine-111 Residue in Heated Cashew Nuts.

Mattison CP, Grimm CC, Li Y, Chial HJ, McCaslin DR, Chung SY, Bren-Mattison Y, Wasserman RL.

J Agric Food Chem. 2017 Jan 18;65(2):411-420. doi: 10.1021/acs.jafc.6b04134. Epub 2017 Jan 6.

PMID:
27966914
16.

The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency.

Wasserman RL.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1076-1081.e3. doi: 10.1016/j.jaip.2016.09.011. Review.

PMID:
27836057
17.

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.

Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, Sharkhawy M, Engl W, Leibl H, Gelmont D, Yel L.

Immunotherapy. 2016 Oct;8(10):1175-86. doi: 10.2217/imt-2016-0066. Epub 2016 Jul 28.

18.

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.

Wasserman RL, Lumry W, Harris J 3rd, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi AL, Du W, Kobayashi R.

J Clin Immunol. 2016 Aug;36(6):590-9. doi: 10.1007/s10875-016-0308-z. Epub 2016 Jun 20.

19.

20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.

Wasserman RL, Stein MR, Younger ME, Fatteh S, Haddad E.

Ann Allergy Asthma Immunol. 2016 Jul;117(1):93-4. doi: 10.1016/j.anai.2016.04.023. Epub 2016 May 26. No abstract available.

PMID:
27236217
20.

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D.

J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25.

21.

Heat-induced alterations in cashew allergen solubility and IgE binding.

Mattison CP, Bren-Mattison Y, Vant-Hull B, Vargas AM, Wasserman RL, Grimm CC.

Toxicol Rep. 2016 Jan 14;3:244-251. doi: 10.1016/j.toxrep.2015.12.009. eCollection 2016.

22.

Treatment with oleic acid reduces IgE binding to peanut and cashew allergens.

Chung SY, Mattison CP, Reed S, Wasserman RL, Desormeaux WA.

Food Chem. 2015 Aug 1;180:295-300. doi: 10.1016/j.foodchem.2015.02.056. Epub 2015 Feb 16.

PMID:
25766831
23.

Subcutaneous immunoglobulin: facilitated infusion and advances in administration.

Wasserman RL.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:75-7. doi: 10.1111/cei.12519. No abstract available.

24.

Hizentra for the treatment of primary immunodeficiency.

Wasserman RL.

Expert Rev Clin Immunol. 2014 Oct;10(10):1293-307. doi: 10.1586/1744666X.2014.957678. Epub 2014 Sep 3. Review.

PMID:
25182658
25.

Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.

Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C, Dasu T, Dave N, De La Morena MT, Duffner U, Fong CT, Forbes L, Freedenberg D, Gelfand EW, Hale JE, Hanson IC, Hay BN, Hu D, Infante A, Johnson D, Kapoor N, Kay DM, Kohn DB, Lee R, Lehman H, Lin Z, Lorey F, Abdel-Mageed A, Manning A, McGhee S, Moore TB, Naides SJ, Notarangelo LD, Orange JS, Pai SY, Porteus M, Rodriguez R, Romberg N, Routes J, Ruehle M, Rubenstein A, Saavedra-Matiz CA, Scott G, Scott PM, Secord E, Seroogy C, Shearer WT, Siegel S, Silvers SK, Stiehm ER, Sugerman RW, Sullivan JL, Tanksley S, Tierce ML 4th, Verbsky J, Vogel B, Walker R, Walkovich K, Walter JE, Wasserman RL, Watson MS, Weinberg GA, Weiner LB, Wood H, Yates AB, Puck JM, Bonagura VR.

JAMA. 2014 Aug 20;312(7):729-38. doi: 10.1001/jama.2014.9132. Erratum in: JAMA. 2014 Nov 26;312(20):2169. Bonagura, Vincent R [Added].

26.

Decreased immunoglobulin E (IgE) binding to cashew allergens following sodium sulfite treatment and heating.

Mattison CP, Desormeaux WA, Wasserman RL, Yoshioka-Tarver M, Condon B, Grimm CC.

J Agric Food Chem. 2014 Jul 16;62(28):6746-55. doi: 10.1021/jf501117p. Epub 2014 Jul 1.

PMID:
24926808
27.
28.

Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.

Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, Paul MM, Sugerman RW, Lee JO, Lester MR, Mendelson LM, Nacshon L, Levy MB, Goldberg MR, Elizur A.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):91-6. doi: 10.1016/j.jaip.2013.10.001.

PMID:
24565775
29.

A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.

Wasserman RL.

Expert Rev Clin Immunol. 2014 Mar;10(3):325-37. doi: 10.1586/1744666X.2014.891438. Review.

PMID:
24527947
30.

Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.

Shapiro RS, Wasserman RL, Bonagura V, Gupta S.

J Clin Immunol. 2017 Feb;37(2):190-196. doi: 10.1007/s10875-014-9990-x. Epub 2014 Jan 30. Review.

PMID:
24477950
31.

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.

Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL.

Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26.

32.

In vitro digestion of soluble cashew proteins and characterization of surviving IgE-reactive peptides.

Mattison CP, Grimm CC, Wasserman RL.

Mol Nutr Food Res. 2014 Apr;58(4):884-93. doi: 10.1002/mnfr.201300299. Epub 2013 Dec 5.

PMID:
24311529
33.

Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks.

Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, Craig TJ.

Adv Ther. 2012 Oct;29(10):913-22. doi: 10.1007/s12325-012-0053-5. Epub 2012 Sep 27.

PMID:
23054691
34.

C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.

Bewtra AK, Levy RJ, Jacobson KW, Wasserman RL, Machnig T, Craig TJ.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):427-31. doi: 10.2500/aap.2012.33.3597.

PMID:
23026185
35.

Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.

Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, Packer F, Bernstein JA, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL.

Allergy Asthma Proc. 2012 Jul-Aug;33(4):354-61. doi: 10.2500/aap.2012.33.3589.

PMID:
22856636
36.

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group.

J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11. doi: 10.1016/j.jaci.2012.06.021. Epub 2012 Jul 28.

PMID:
22846381
37.

Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Wasserman RL.

J Clin Immunol. 2012 Dec;32(6):1153-64. doi: 10.1007/s10875-012-9740-x. Epub 2012 Jul 25. Review.

PMID:
22828788
38.

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, Wasserman RL, Baggish JS, Saunders R, Grimbacher B.

Clin Exp Immunol. 2012 Aug;169(2):172-81. doi: 10.1111/j.1365-2249.2012.04594.x.

39.

Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM.

J Clin Immunol. 2012 Aug;32(4):663-9. doi: 10.1007/s10875-012-9656-5. Epub 2012 Mar 6.

40.

Safety of L-proline as a stabilizer for immunoglobulin products.

Hagan JB, Wasserman RL, Baggish JS, Spycher MO, Berger M, Shashi V, Lohrmann E, Sullivan KE.

Expert Rev Clin Immunol. 2012 Feb;8(2):169-78. doi: 10.1586/eci.11.97. Review. Erratum in: Expert Rev Clin Immunol. 2012 May;8(4):.

PMID:
22288455
41.

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.

Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL.

Allergy. 2011 Dec;66(12):1604-11. doi: 10.1111/j.1398-9995.2011.02702.x. Epub 2011 Sep 2.

PMID:
21884533
42.

Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA.

Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000.

PMID:
21553933
43.

Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.

Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ.

J Clin Immunol. 2011 Jun;31(3):323-31. doi: 10.1007/s10875-011-9512-z. Epub 2011 Mar 22.

PMID:
21424824
44.

Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity.

Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtułowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Craig TJ.

Allergy Asthma Proc. 2011 Jan-Feb;32(1):36-42. doi: 10.2500/aap.2011.32.3404.

PMID:
21262096
45.

Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks.

Wasserman RL, Levy RJ, Bewtra AK, Hurewitz D, Craig TJ, Kiessling PC, Keinecke HO, Bernstein JA.

Ann Allergy Asthma Immunol. 2011 Jan;106(1):62-8. doi: 10.1016/j.anai.2010.10.012. Epub 2010 Nov 20.

PMID:
21195947
46.

Office-based oral immunotherapy for food allergy is safe and effective.

Wasserman RL, Sugerman RW, Mireku-Akomeah N, Mansfield L, Baker JW.

J Allergy Clin Immunol. 2011 Jan;127(1):290-1; author reply 291-2. doi: 10.1016/j.jaci.2010.08.052. Epub 2010 Oct 30. No abstract available.

PMID:
21040956
47.

Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease.

Greenberg DE, Shoffner AR, Zelazny AM, Fenster ME, Zarember KA, Stock F, Ding L, Marshall-Batty KR, Wasserman RL, Welch DF, Kanakabandi K, Sturdevant DE, Virtaneva K, Porcella SF, Murray PR, Malech HL, Holland SM.

Emerg Infect Dis. 2010 Sep;16(9):1341-8. doi: 10.3201/eid1609.091800.

48.

Diagnosis and treatment of primary immunodeficiency disease: the role of the otolaryngologist.

Wasserman RL, Manning SC.

Am J Otolaryngol. 2011 Jul-Aug;32(4):329-37. doi: 10.1016/j.amjoto.2010.05.001. Epub 2010 Aug 17. Review.

PMID:
20724030
49.

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.

Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Schindel F, Craig TJ.

Ann Allergy Asthma Immunol. 2010 Aug;105(2):149-54. doi: 10.1016/j.anai.2010.06.005. Erratum in: Ann Allergy Asthma Immunol. 2011 Jan;106(1):78.

PMID:
20674826
50.

Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.

Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang WH, Keinecke HO, Kiessling PC.

J Clin Immunol. 2010 Nov;30(6):823-9. doi: 10.1007/s10875-010-9442-1. Epub 2010 Jul 16.

Supplemental Content

Loading ...
Support Center